Coronavirus disease 2019 in a psoriatic patient with concomitant chronic obstructive pulmonary disease under treatment with risankizumab

Abstract

With the emergence of the coronavirus disease 2019 (COVID-19) pandemic, concern has risen among physicians if treatment with biologic agents for psoriasis may result in a more severe disease course. 1,2 To date, only a limited number of cases have been published on the outcomes of COVID-19 infection in psoriatic patients under guselkumab, ustekinumab, adalimumab and secukinumab treatment, 3-5 yet no such case was reported on patients receiving risankizumab therapy. Here, we report on a 77-year-old male patient who has been suffering from chronic plaque psoriasis for 18 years, previously treated with several conventional and biologic drugs, including cyclosporine, methotrexate, infliximab, ustekinumab and secukinumab. The patient was switched to risankizumab 8 months ago as the last biologic agent, secukinumab, caused episodes of diarrhea. The patient's medical history included various diseases relevant to his psoriasis, such as rheumatoid arthritis, hypertension, acute myocardial infarction 20 years ago and chronic obstructive pulmonary disease (COPD) for 15 years.

Correlation Analysis Between Serum Uric Acid, Prealbumin Level, Lactate Dehydrogenase, and Severity of COVID-19

“…COVID-19 is an infectious disease mainly spread by droplets . It spreads quickly and is a severe disease that poses a great threat to people's health ( Kahn et al, 2020 ; Kim et al, 2020 ; Kiss et al, 2020 ; Lim and Claydon, 2020 ). As this is a recently discovered disease, there is no conclusion on its pathogenesis and risk factors ( Djulbegovic et al, 2020 ).…”

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments

“…Data retrieved from case-control studies, cohort studies and case reports showed full recovery form COVID-19 after synthetic and biologic DMARDs treatment interruption. Rarely these patients required hospitalization [16][17][18][19][20][21]. Favorable outcomes of COVID-19 infection in patients who continued apremilast and certain biologics, such as adalimumab, ustekinumab, ixekizumab and guselkumab, were also reported [6,[22][23][24][25][26].…”

“…The pandemic of coronavirus disease (COVID- 19), a viral pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has raised serious concern among dermatologists and psoriatic patients receiving systemic immunomodulating/immunosuppressive treatments [1]. Plaque psoriasis is a chronic inflammatory skin disease affecting 2-3% of the general population, and approximately one-third of patients are candidates for systemic treatments because of disease severity, extensions and/or localization in sensitive or visible areas (Figure 1) [2].…”

SARS-CoV-2 infection in a patient with psoriasis treated with risankizumab

“…Prior reports have linked Th17 to severe immune injury in SARS-CoV-2 infection [2,3]. This data has led some authors to propose that inhibition of IL23, which is essential to Th17 phenotype, may play a protective role in the setting of SARS-CoV-2 infection by attenuating key cytokines [4][5][6].…”